Comparative Pharmacology
Head-to-head clinical analysis: ALCAFTADINE versus ELESTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALCAFTADINE versus ELESTAT.
ALCAFTADINE vs ELESTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.
Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells.
1 drop of 0.25% ophthalmic solution in each affected eye twice daily.
1 drop (0.05% ophthalmic solution) in the affected eye twice daily approximately every 12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1.5–3 h) after topical ocular administration, appropriate for twice-daily dosing.
Clinical Note
moderateAlcaftadine + Betahistine
"The therapeutic efficacy of Betahistine can be decreased when used in combination with Alcaftadine."
Clinical Note
moderateAmphetamine + Alcaftadine
"Amphetamine may decrease the sedative activities of Alcaftadine."
Clinical Note
moderateDiethylpropion + Alcaftadine
"Diethylpropion may decrease the sedative activities of Alcaftadine."
Clinical Note
moderatePhentermine + Alcaftadine
Terminal elimination half-life is approximately 8-12 hours in healthy adults; clinically, twice-daily dosing maintains therapeutic concentrations.
Primarily renal (approximately 50% unchanged), with the remainder as metabolites; negligible biliary/fecal elimination.
Primarily renal excretion of unchanged drug (approx. 60-70%) and metabolites; biliary/fecal excretion accounts for 20-30%.
Category C
Category C
Ophthalmic Antihistamine
Ophthalmic Antihistamine
"Phentermine may decrease the sedative activities of Alcaftadine."